Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1503 Alone and with Pembrolizumab in Advanced Tumors
NCT03775850Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, open-label trial of edp1503 in colorectal cancer (CRC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 4 more (3 arms), sponsored by Evelo Biosciences. Primary endpoints: Safety and tolerability of EDP1503 alone and in combination with pembrolizumab at 2 years and Objective Response Rate at 2 years. Started Dec 2018; status: completed.
02
Drugs
edp1503
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)bladder cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03775850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775850.